Short answer
Cooper Companies (The) (COO) filed its fiscal 2025 10-K annual report with the SEC on Dec 5, 2025. It reported revenue of $4.1B (+5.1% year over year) and net income of $375M.
- Top risk flagged: Regulatory risk: FDA and NMPA approvals for MiSight 1 day lens to slow myopia progression in children aged 8-12, critical for market penetration in US, China, and Japan
FY2025 key financial metrics · XBRL
- Revenue
- $4.1B
- +5.1% YoY
- Net income
- $375M
- −4.4% YoY
- Operating margin
- 16.7%
- −1.4 pp YoY
- Gross margin
- 65.5%
- −1.1 pp YoY
- EPS (diluted)
- $1.87
- −4.6% YoY
- ROE
- 4.6%
- −0.3 pp YoY
- Operating cash flow
- $796M
- +12.2% YoY
Source: XBRL data from the Cooper Companies (The) (COO) FY2025 10-K on SEC EDGAR. USD.
Cooper Companies (The) FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model: global medical device company with two segments, CooperVision and CooperSurgical, focused on vision, fertility, and women’s health
- Expanded geographic reach, selling products in over 130 countries
- Positive impact on over 50 million lives annually reported
- Headquartered in San Ramon, California, emphasizing global leadership in medical devices
Management Discussion & Analysis
- Outlook optimistic on long-term contact lens and general health care market growth
- Risks and uncertainties acknowledged in global operating environment
Risk Factors
- Regulatory risk: FDA and NMPA approvals for MiSight 1 day lens to slow myopia progression in children aged 8-12, critical for market penetration in US, China, and Japan
- Macroeconomic exposure: 5% net sales growth in Americas and 8% in EMEA, driven by silicone hydrogel lenses, with revenue positively impacted by $16 million favorable foreign exchange in 2025
- Operational vulnerability: Inventory and long-lived asset write-offs and severance costs from workforce optimization initiatives negatively impacted gross margin and operating income in CooperSurgical in 2025
- Competitive risk: Market competition in contact lenses from products with advancing technology such as silicone hydrogel lenses (Biofinity, MyDay) and myopia management lenses
- Financial risk: High leverage with $2.456 billion borrowings against a $3.8 billion credit facility and $100 million interest expense, with $966 million authorized but unspent for share repurchases as of October 31, 2025
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.